Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

Preclinical and Clinical Presentations Include Update on FRAME Study Low-Grade Serous Ovarian Cancer Efficacy Data

...

Related Keywords

United States ,London ,City Of ,United Kingdom ,Massachusetts ,Boston ,American ,Udai Banerji ,Dan Paterson ,Jonathan Pachter ,Louis Denis ,Institute Of Cancer Research ,Nasdaq ,Drug Development Unit ,Amgen ,Drug Administration ,Raf And Mek Program ,American Society Of Clinical Oncology ,Drug Development Summit ,Verastem Oncology ,Targeted Drug Development Summit ,Chief Scientific Officer ,Chief Medical Officer ,Enhancing Antitumor Efficacy ,Rational Combinations ,Breakthrough Therapy Designation ,Chief Executive Officer ,Professor Udai Banerji ,Deputy Director ,Cancer Research ,Royal Marsden ,American Society ,Clinical Oncology ,Breakthrough Therapy ,Markets ,